Breaking News Instant updates and real-time market news.

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25

Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies

Unum Therapeutics announced Phase 1 clinical updates for its Antibody-Coupled T cell Receptor engineered T-cell therapies, ACTR707 and ACTR087, in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma. "The clinical data presented at this year's ASH include updates from the ongoing Phase 1 trial of ACTR707 in combination with rituximab and the completed Phase 1 trial of ACTR087 in combination with rituximab, both conducted in patients with relapsed or refractory CD20+ NHL," said Jessica Sachs, M.D., Chief Medical Officer of Unum. "The data with ACTR707 at this year's ASH continue to support further dose-escalation in this Phase 1 trial and provide proof-of-mechanism for the ACTR platform that we are also applying in our lead program, a Phase 1 trial with ACTR707 in combination with trastuzumab in HER2+ solid tumor cancers. Safety data from the Phase 1 trial with ACTR087 presented at this year's ASH provide learnings that are being applied to ongoing clinical trials with ACTR T cell products. A complete response was achieved in 40% of patients in Cohorts 1 through 4. Of the eight complete responders, four remained in complete response at six months of follow-up, two remain in complete response but have not yet reached the six-month timepoint for evaluation, and two progressed before the six-month timepoint.

  • 07

    Dec

UMRX Unum Therapeutics
$0.70

0.0177 (2.61%)

07/03/19
RHCO
07/03/19
NO CHANGE
Target $6
RHCO
Buy
Unum Therapeutics price target lowered to $6 from $10 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Unum Therapeutics to $6 after yesterday's FDA announcement of a clinical hold on its Phase 1 trial ATTCK-20-2 evaluating ACTR087 in combination with rituximab. The analyst is retaining a Buy rating on the stock however, stating that his discussions with the management indicated the program was already de-prioritized in November of 2018 "in favor of the '707 construct", and the hold should yield a limited read through to other programs.
07/03/19
COWN
07/03/19
NO CHANGE
COWN
Market Perform
Unum Therapeutics clinical hold not an issue, says Cowen
Cowen analyst Yaron Werber noted the FDA placed a clinical hold on ACTR087 adding to ongoing concerns about the potential of its platform given lackluster efficacy data. The analyst said the hold is not an issue as it was deprioritized and the prospects for the stock may lie in the BOXR platform. Werber maintained his Market Perform rating on Unum Therapeutics shares.
07/03/19
HCWC
07/03/19
NO CHANGE
Target $18
HCWC
Buy
Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright
Unum Therapeutics shares overreacted yesterday to news of a clinical hold on the Phase 1 trial ATTCK-20-2, which may provide an attractive entry point, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst says that although the clinical hold raises concerns on potential "narrower-than-expected therapeutic window" of ACTR-087 in B-cell malignancies, his comfort in a positive outlook of ATTCK-20-02 and ACTR-T cells in general is derived from the fact that approved CAR-T therapies, Kymriah and Yescarta, are both associated with similar serious adverse events. The analyst reiterates a Buy rain on Unum Therapeutics with an $18 price target ahead of the company's multiple data in 2019.
08/13/19
WEDB
08/13/19
NO CHANGE
Target $13
WEDB
Outperform
Unum Therapeutics price target lowered to $13 from $20 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Unum Therapeutics to $13 from $20, while reiterating an Outperform rating on the shares. The analyst notes that the company provided a preliminary update from the Phase 1 ATTCK-20-03 trial of ACTR707 + rituximab combo in r/r B-cell non-Hodgkin lymphoma with data from Cohort 3, which had a complete response of 20% and an overall response rate of 80%. Although the analyst acknowledges that it was "encouraging" to see a higher response rate in Cohort 3, the slip in CR rate is "difficult to overlook," given a CR of 50% and 33% in Cohorts 1 and 2, respectively. Nonetheless, Nierengarten sees the data readouts in the second half of 2019 as opportunity to lend credibility to Unum Therapeutics' platform and provide upside to the company's valuation.

TODAY'S FREE FLY STORIES

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.